Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions

Incidence and Economic Burden of Adverse Drug Reactions among Elderly Patients in Ontario Emergency Departments

(2013) Chen Wu et al.   DRUG SAFETY

A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing

(2013) Stephen E. Kimmel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel

(2012) Emily S. Reese et al.   PHARMACOTHERAPY

Adverse Drug Events in U.S. Adult Ambulatory Medical Care

(2011) Urmimala Sarkar et al.   HEALTH SERVICES RESEARCH

Emergency Hospitalizations for Adverse Drug Events in Older Americans

(2011) Daniel S. Budnitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Warfarin Genotyping Reduces Hospitalization Rates

(2010) Robert S. Epstein et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The Case for Routine Genotyping in Dual-Antiplatelet Therapy

(2010) Samir B. Damani et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Markov Decision Processes: A Tool for Sequential Decision Making under Uncertainty

(2010) Oguzhan Alagoz et al.   MEDICAL DECISION MAKING

Adverse drug events in the outpatient setting: an 11-year national analysis

(2010) Florence T. Bourgeois et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic? A Cost-effectiveness Analysis Based on Data from the STAR*D Study

(2009) Roy H Perlis et al.   NEUROPSYCHOPHARMACOLOGY

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment

(2008) D F Heitjan et al.   PHARMACOGENOMICS JOURNAL